The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.
The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
George Church's Nebula is teaming with Hong Kong startup Longenesis to create a secure platform for individuals and biobanks to sell access to their genomes.
The Israeli biotechnology firm hopes that a successful outcome of the study with Centre Léon-Bérard will raise its profile among oncologists.
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
The Healthy Nevada Project will enroll an additional 40,000 participants to be exome sequenced through Helix and receive a free app from its online genomics marketplace.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
The companies will combine Empire's NGS services and FISH probe portfolio with Kromatid's Pinpoint probes and directional genomic hybridization technology.
With its recently launched BCRquest.com data analysis hub, BC Platforms has teamed with the Accelerated Cure Project for MS and Biogen.
Living DNA and its partners are aiming to create a detailed genetic map of the world based on people's DNA.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.